Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

119 – Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH

Background Drug-drug interactions (DDIs) between contraceptives and antiretroviral therapy (ART) may increase the risk of unintended pregnancy and side effects. The levonorgestrel (LNG) implant and depot medroxyprogesterone acetate (DMPA) injectable are commonly used contraceptives in women living with HIV (WLWH), but pharmacokinetic (PK) data evaluating DDIs between dolutegravir (DTG) and LNG or MPA are lacking.…

160 – Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening

Background As syphilis rates rise, emergency department (ED) screening has been proposed as an important opportunity for early diagnosis and treatment of syphilis, especially for communities with limited access to care, for whom the ED visit may represent their primary contact with the healthcare system. Given potential increased costs and resources needed for universal screening,…

162 – DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC

Background Doxycycline post-exposure prophylaxis (DoxyPEP) use can significantly reduce the incidence of bacterial sexually transmitted infections (STIs), yet uptake has been low among people with HIV (PWH). In Washington, DC, high rates of STIs have been observed among PWH. We assessed STI diagnosis rates, DoxyPEP eligibility, use, and the potential impact of DoxyPEP prescribing on…

163 – High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation

Background Doxycycline for post-exposure prophylaxis (DPEP) is highly effective for preventing bacterial sexually transmitted infections (STIs) in clinical trials; however recent real-world data suggests lack of effectiveness for gonorrhea. We examined the impact of DPEP on STIs (syphilis, chlamydia, and gonorrhea) in clients at a large sexual health clinic in San Francisco, CA, US. Methods…

161 – Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis

Background Congenital syphilis (CS) is an urgent threat; cases are at their highest rate (102.5/100,000 live births) since 1991. The only treatment (tx) for late latent syphilis (LLS) in pregnancy is 3 doses of benzathine penicillin G (BPGx3), given at 7-day (d) intervals. If intervals exceed 9d, US guidelines recommend restarting the full tx series,…

113 – Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV

Background In a recent pilot study (ACTG A5371, SLIM LIVER: NCT04216589), 24 weeks of low-dose semaglutide (1 mg sc weekly) reduced metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV (PWH), with 58% having improved MRI-proton-derived fat fraction-quantified intrahepatic triglycerides (IHTG). Although trends suggested greater IHTG improvements in women and older participants, the role…

122 – Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study

Background Dolutegravir (DTG) is not recommended for neonates due to absence of dosing guidelines and safety information. We are evaluating the multi-dose pharmacokinetics (PK) and safety of two pediatric DTG formulations in neonates: a dispersible scored tablet (DTG-DT, 10 mg) and a novel oral dispersible film (DTG-OF, 5 mg). Methods PETITE-DTG is an ongoing phase…

124 – Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma

Background Kaposi sarcoma (KS), caused by KS herpesvirus (KSHV), is a multicentric angioproliferative tumor seen in people with and without HIV. Abemaciclib (Abema) is an oral cyclin-dependent kinase (CDK) inhibitor that targets CDK4 (cyclin D1) and CDK6 (cyclin D3) that is FDA-approved for breast cancer. In vitro studies of KSHV-infected cells have shown that CDK4/6…

128 – All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania

Background Comparing cause-specific mortality among people with HIV (PWH) and people without HIV (PWOH) is important for tracking improved survival following increased antiretroviral therapy (ART) access. However, comprehensive data on cause-specific mortality rates in Sub-Saharan Africa remains inadequate. We estimated mortality trends in Tanzania.  Methods Data were collected in a health and demographic surveillance system…

125 – Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer

Background People with HIV (PWH) are at increased risk of oropharynx cancer (OPC) compared with people without HIV (PWoH). PWH and OPC also have poorer survival compared to PWoH and OPC. However, prior studies have not evaluated OPC treatment initiation and survival among cohorts of PWH and PWoH matched on demographic variables, stage, and HPV…